#United States #Dividend #Shareholders #AbbVie #North Chicago

AbbVie Declares Quarterly Dividend

On February 13, 2025, AbbVie Inc., a notable player in the pharmaceutical industry, declared a quarterly cash dividend of $1.64 per share. This announcement, made by the board of directors, marks a continuation of the company's strong commitment to rewarding its shareholders. The dividend will be payable on May 15, 2025, to stockholders who hold shares at the close of business on April 15, 2025.

Since AbbVie's founding in 2013, the company has impressively increased its dividend by 310%. This growth in dividends not only underscores the company's profitability but also enhances its standing as a reliable investment option for shareholders. AbbVie is a proud member of the S&P Dividend Aristocrats Index, which includes companies that have raised their dividends annually for a minimum of 25 consecutive years, highlighting its financial stability and dedication to long-term growth.

AbbVie’s mission extends beyond financial success; it is dedicated to discovering and delivering innovative medicines and solutions to address serious health challenges and meet the medical needs of tomorrow. The company's efforts span various therapeutic areas, including immunology, oncology, neuroscience, and eye care. Additionally, AbbVie continues to expand its portfolio with products and services in its Allergan Aesthetics division, further broadening its impact within the healthcare sector.

The strategic focus on innovation and responsiveness to medical needs positions AbbVie well, not just for immediate financial objectives, but for sustainable growth and development in the healthcare landscape of the future. As the company prioritizes high-quality research and development alongside robust dividend offerings, it remains committed to enhancing the quality of life for patients worldwide.

With increased dividends and ongoing investments in transformative medical research, AbbVie is showcasing its strong vision for the future. Investors are not only gaining financial returns through dividends but also contributing to advancements in medical science and patient care. This reflects a dual commitment to business success and societal benefit that many investors find appealing.

For those interested in staying updated on AbbVie’s activities, the company encourages following them across various social media platforms, including LinkedIn, Facebook, Instagram, Twitter (now X), and YouTube. For more detailed information about AbbVie’s financial health and strategic initiatives, interested parties can visit the official website at www.abbvie.com.

Contact Information

For media inquiries, Gabby Tarbert is available at (224) 244-0111. Investors can reach out to Liz Shea at (847) 935-2211 for additional insights and information.

In conclusion, AbbVie’s quarterly dividend declaration serves as a testimony to its strong financial foundations and commitment to shareholder value. As the company continues to navigate the ever-evolving pharmaceutical landscape, it remains dedicated to delivering results that benefit both its investors and the global community.